NEW YORK (GenomeWeb) — HTG Molecular Diagnostics announced today that it has signed a master agreement to help Oncologie develop biomarkers for its immuno-oncology drug candidates.
Specific terms of the deal were not disclosed.
Oncologie currently has two drugs in its pipeline: the phase II immune-modulatory monoclonal antibody bavituximab, and the phase III immunomodulator and toll-like receptor 9 agonist lefitolimod. HTG offers next-generation sequencing-based molecular profiling instruments and assays, as well as related lab services.
“We believe HTG’s technology and assay development capabilities will assist our clinical development efforts as we strive to bring innovative new medicines to cancer patients globally,” Oncologie Founder and CEO Laura Benjamin said in a statement.